Evidence map›Paper›PMID 27138845›Full record

ArticleStem cell reviews and reports2016

Functionalizing Ascl1 with Novel Intracellular Protein Delivery Technology for Promoting Neuronal Differentiation of Human Induced Pluripotent Stem Cells.

Meghan Robinson, Parv Chapani, Tara Styan, Ranjani Vaidyanathan, Stephanie Michelle Willerth

Abstract read
PubMed Publisher
In one paragraph

Article in Stem cell reviews and reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Meghan RobinsonBiomedical Engineering Program, University of Victoria, Victoria, BC, Canada.
Parv ChapaniDepartment of Biochemistry, University of Victoria, Victoria, BC, Canada.
Tara StyanBiomedical Engineering Program, University of Victoria, Victoria, BC, Canada.
Ranjani VaidyanathaniProgen Biotech, Inc., Vancouver, BC, Canada.
Stephanie Michelle WillerthDepartment of Mechanical Engineering, University of Victoria, Victoria, BC, Canada. willerth@uvic.ca.
University of Victoria · CAiProgen Biotech (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pluripotent stem cells can become any cell type found in the body. Accordingly, one of the major challenges when working with pluripotent stem cells is producing a highly homogenous population of differentiated cells, which can then be used for downstream applications such as cell therapies or drug screening. The transcription factor Ascl1 plays a key role in neural development and previous work has shown that Ascl1 overexpression using viral vectors can reprogram fibroblasts directly into neurons. Here we report on how a recombinant version of the Ascl1 protein functionalized with intracellular protein delivery technology (Ascl1-IPTD) can be used to rapidly differentiate human induced pluripotent stem cells (hiPSCs) into neurons. We first evaluated a range of Ascl1-IPTD concentrations to determine the most effective amount for generating neurons from hiPSCs cultured in serum free media. Next, we looked at the frequency of Ascl1-IPTD supplementation in the media on differentiation and found that one time supplementation is sufficient enough to trigger the neural differentiation process. Ascl1-IPTD was efficiently taken up by the hiPSCs and enabled rapid differentiation into TUJ1-positive and NeuN-positive populations with neuronal morphology after 8 days. After 12 days of culture, hiPSC-derived neurons produced by Ascl1-IPTD treatment exhibited greater neurite length and higher numbers of branch points compared to neurons derived using a standard neural progenitor differentiation protocol. This work validates Ascl1-IPTD as a powerful tool for engineering neural tissue from pluripotent stem cells.

Indexed as

Gene Transfer TechniquesAntigens, NuclearBasic Helix-Loop-Helix ProteinsBlotting, WesternCell Culture TechniquesCell DifferentiationCell LineCulture Media, Serum-FreeHumansImmunohistochemistryInduced Pluripotent Stem CellsNerve Tissue ProteinsNeuronsTime FactorsTubulinAntigens, NuclearASCL1 protein, humanBasic Helix-Loop-Helix ProteinsCulture Media, Serum-FreeNerve Tissue Proteinsneuronal nuclear antigen NeuN, humanTUBB3 protein, humanTubulinDrug deliveryIntracellular targetingNeurite extensionNeuroscienceProteinsStem cells

Identifiers

PMID27138845
OpenAlexW2347129963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.